Paul Blanchfield Sells 1,500 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH) President Paul Blanchfield sold 1,500 shares of the business’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $67.96, for a total transaction of $101,940.00. Following the completion of the sale, the president now owns 88,651 shares in the company, valued at $6,024,721.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Lantheus Price Performance

Shares of LNTH stock traded up $0.92 during mid-day trading on Monday, reaching $69.12. The company’s stock had a trading volume of 528,807 shares, compared to its average volume of 1,013,518. The firm’s 50-day moving average is $66.53 and its two-hundred day moving average is $77.17. The company has a market cap of $4.73 billion, a P/E ratio of 48.40 and a beta of 0.66. Lantheus Holdings, Inc. has a 1-year low of $47.46 and a 1-year high of $100.85. The company has a debt-to-equity ratio of 0.80, a quick ratio of 5.05 and a current ratio of 5.37.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Macquarie Group Ltd. raised its holdings in shares of Lantheus by 21.7% in the 1st quarter. Macquarie Group Ltd. now owns 605 shares of the medical equipment provider’s stock worth $50,000 after buying an additional 108 shares in the last quarter. US Bancorp DE raised its stake in Lantheus by 2.2% during the first quarter. US Bancorp DE now owns 7,204 shares of the medical equipment provider’s stock worth $595,000 after acquiring an additional 153 shares in the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Lantheus by 36.6% during the third quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock valued at $40,000 after acquiring an additional 156 shares during the period. Covestor Ltd boosted its stake in shares of Lantheus by 102.5% in the 2nd quarter. Covestor Ltd now owns 324 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 164 shares in the last quarter. Finally, RFG Advisory LLC boosted its stake in shares of Lantheus by 4.4% in the 3rd quarter. RFG Advisory LLC now owns 3,940 shares of the medical equipment provider’s stock valued at $274,000 after purchasing an additional 167 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on LNTH. JMP Securities decreased their price target on Lantheus from $130.00 to $100.00 and set a “market outperform” rating for the company in a research report on Friday, November 3rd. TheStreet upgraded Lantheus from a “c” rating to a “b-” rating in a report on Wednesday, August 9th. Truist Financial reissued a “buy” rating and issued a $110.00 price objective on shares of Lantheus in a research note on Wednesday, October 4th. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Monday, November 6th. Finally, Mizuho reiterated a “buy” rating and set a $125.00 price target on shares of Lantheus in a report on Wednesday, October 4th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $115.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.